CNTX Wutah bathi EPS kuartalan Context Therapeutics Inc.

Expense optimization through research outsourcing minimizes capital expenditures for Context Therapeutics (CNTX). Quarterly EPS growth intensity demonstrates a steady trend, with the value holding at 21.30. Patent portfolio transparency and the strategic allocation of R&D funds strengthen the company's position. Market confidence is based on Martin Ler's leadership and the availability of a substantial liquidity reserve for the development of targeted breast cancer therapy.

Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan contexttherapeutics.com (CNTX): kanggo periode 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Context Therapeutics

- nilai pasar lan prakiraan target analis:

Bagan rega Context Tx|CNTX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Context Tx|CNTX - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Context Therapeutics|CNTX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku contexttherapeutics.com|CNTX - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Utang marang Ekuitas Context Therapeutics|CNTX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Context Therapeutics|CNTX - Utang agregat perusahaan|Utang marang nilai buku Context Tx|CNTX - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Context Therapeutics|Indikator likuiditas cepet contexttherapeutics.com

- rincian bathi lan kelipatan pasar:

CNTX - Bathi perusahaan|Bathi mangsa ngarep Context Therapeutics|CNTX - Rasio rega pasar marang bathi resik|Prakiraan rega marang bathi Context Tx|CNTX - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Context Tx|CNTX - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Context Therapeutics|CNTX - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan contexttherapeutics.com|CNTX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Context Therapeutics

- statistik dodolan lan pendapatan perusahaan:

CNTX - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Context Therapeutics Inc.|CNTX - Multiplikator P/S|Rasio rega marang prakiraan pendapatan CNTX|CNTX - Wutah dodolan taun lumaku

Ringkesan analisis perusahaan:Context Therapeutics Inc, CNTX

Produk asil prodhuksi contexttherapeutics.com

Professional capital evaluates Context Therapeutics (CNTX) through the lens of cost management efficiency regarding the outsourcing of clinical trials and protein synthesis. By analyzing the quarterly EPS growth vector, the investor determines the rate of net income per share increase, which allows for the differentiation of short-term volatility from a sustainable recovery in operating profitability and confirms the fundamental reliability of the asset.

Analisis pesaing Context Therapeutics

Merus Therapeutics (MRUS) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan Immutep Limited ADR|ANIX (Anixa Biosciences) - Wutah bathi EPS kuartalan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan atossatherapeutics.com ATOS|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Mersana (MRSN)|BriaCell - Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan EPIX (ESSA Pharma)|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan QTI (QT Imaging Holdings, Inc.)